Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023)
Pacific Biosciences Of California (PACB) recorded quarterly Restructuring Costs of $63000.0 in Q4 2023, down 99.3% quarter-over-quarter from $9.0 million in Q3 2023.
Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023) Analysis & Trends
Pacific Biosciences Of California's Restructuring Costs history runs 2 years deep, the most recent figure standing at $63000.0 for Q4 2023.
- In Q4 2023, Restructuring Costs changed N/A year-over-year to $63000.0; the TTM figure through Dec 2024 stood at $9.0 million (changed N/A YoY), while the FY2023 annual figure was $9.0 million, changed N/A from the prior year.
- Restructuring Costs was $63000.0 for Q4 2023 at Pacific Biosciences Of California, down from $9.0 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $12.0 million in Q3 2021 to a low of $63000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 426.62 Mn | 150.66 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | 8.98 Mn |
| Dec 31, 2021 | 403,000.00 |
| Sep 20, 2021 | 12.00 Mn |